DRUG · Mapped RxNorm record
Palbociclib
Normalized identity: palbociclibView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
NCT04567420
Drugs and interventions used in this trial
3 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
Fulvestrant
Normalized identity: fulvestrantView linked drug · Find medicine records ·
Find other trials using this name
DRUG · Unmapped registry intervention
Adjuvant Therapy
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedDNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
Design: INTERVENTIONAL · Status: ACTIVE NOT RECRUITING · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Breast Cancerverified · MONDO: breast cancer
Interventions
PalbociclibDRUG · verified · RxNorm: palbociclib
FulvestrantDRUG · verified · RxNorm: fulvestrant
Adjuvant TherapyDRUG
Sponsors & collaborators
Criterium, Inc.lead sponsor
Mapped research locations
Los AngelesCalifornia, United States2New YorkNew York, United States1AtlantaGeorgia, United States1SeattleWashington, United States1ColumbusOhio, United States1PortlandOregon, United States1AuroraColorado, United States1Oklahoma CityOklahoma, United States1New HavenConnecticut, United States1RichmondVirginia, United States1TucsonArizona, United States1New OrleansLouisiana, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04567420 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.